Disc Medicine, Inc. (NASDAQ:IRON - Get Free Report) Director Mona Ashiya sold 5,738 shares of the firm's stock in a transaction dated Monday, March 24th. The stock was sold at an average price of $54.11, for a total value of $310,483.18. Following the transaction, the director now owns 186,541 shares in the company, valued at approximately $10,093,733.51. This trade represents a 2.98 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.
Mona Ashiya also recently made the following trade(s):
- On Friday, March 21st, Mona Ashiya sold 10,011 shares of Disc Medicine stock. The shares were sold at an average price of $54.00, for a total transaction of $540,594.00.
- On Wednesday, March 19th, Mona Ashiya sold 39,656 shares of Disc Medicine stock. The shares were sold at an average price of $54.02, for a total transaction of $2,142,217.12.
- On Wednesday, March 12th, Mona Ashiya sold 83,182 shares of Disc Medicine stock. The stock was sold at an average price of $54.45, for a total value of $4,529,259.90.
- On Monday, March 10th, Mona Ashiya sold 202,146 shares of Disc Medicine stock. The stock was sold at an average price of $54.29, for a total value of $10,974,506.34.
Disc Medicine Trading Down 0.6 %
NASDAQ IRON opened at $52.49 on Thursday. The company has a market cap of $1.81 billion, a price-to-earnings ratio of -13.19 and a beta of 0.73. Disc Medicine, Inc. has a 1-year low of $25.60 and a 1-year high of $68.73. The company has a 50 day moving average of $54.90 and a 200-day moving average of $56.13.
Disc Medicine (NASDAQ:IRON - Get Free Report) last issued its quarterly earnings results on Thursday, February 27th. The company reported ($0.98) EPS for the quarter, topping analysts' consensus estimates of ($1.06) by $0.08. On average, equities research analysts forecast that Disc Medicine, Inc. will post -4.07 earnings per share for the current year.
Wall Street Analyst Weigh In
A number of brokerages recently weighed in on IRON. Morgan Stanley reaffirmed an "overweight" rating and issued a $85.00 target price on shares of Disc Medicine in a research note on Friday, March 7th. Stifel Nicolaus raised their price target on shares of Disc Medicine from $90.00 to $94.00 and gave the stock a "buy" rating in a research note on Friday, January 24th. Wedbush restated an "outperform" rating and set a $90.00 target price (up previously from $83.00) on shares of Disc Medicine in a report on Tuesday, January 21st. Scotiabank increased their price objective on shares of Disc Medicine from $73.00 to $75.00 and gave the stock a "sector outperform" rating in a research note on Monday, March 3rd. Finally, HC Wainwright restated a "buy" rating and issued a $118.00 price target on shares of Disc Medicine in a research note on Tuesday, January 21st. Ten investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of "Buy" and an average target price of $93.80.
View Our Latest Research Report on IRON
Institutional Trading of Disc Medicine
Institutional investors and hedge funds have recently made changes to their positions in the company. Sterling Capital Management LLC raised its position in Disc Medicine by 798.4% during the fourth quarter. Sterling Capital Management LLC now owns 566 shares of the company's stock valued at $36,000 after purchasing an additional 503 shares in the last quarter. GF Fund Management CO. LTD. bought a new stake in shares of Disc Medicine during the 4th quarter worth $40,000. Tower Research Capital LLC TRC grew its position in Disc Medicine by 47.6% in the fourth quarter. Tower Research Capital LLC TRC now owns 825 shares of the company's stock valued at $52,000 after acquiring an additional 266 shares during the last quarter. Quest Partners LLC bought a new position in shares of Disc Medicine in the third quarter worth about $131,000. Finally, Quantbot Technologies LP acquired a new stake in shares of Disc Medicine in the 3rd quarter valued at approximately $146,000. Institutional investors own 83.70% of the company's stock.
About Disc Medicine
(
Get Free Report)
Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to contact@insidertrades.com.
